Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors
dc.contributor.author | Edinoff, A.N. | |
dc.contributor.author | Swinford, C.R. | |
dc.contributor.author | Odisho, A.S. | |
dc.contributor.author | Burroughs, C.R. | |
dc.contributor.author | Stark, C.W. | |
dc.contributor.author | Raslan, W.A. | |
dc.contributor.author | Cornett, E.M. | |
dc.contributor.author | Kaye, A.M. | |
dc.contributor.author | Kaye, A.D. | |
dc.date.accessioned | 2023-01-31T18:18:49Z | |
dc.date.available | 2023-01-31T18:18:49Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Edinoff, A. N., Swinford, C. R., Odisho, A. S., Burroughs, C. R., Stark, C. W., Raslan, W. A., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2022). Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors. Health Psychology Research, 10(4). | |
dc.identifier.issn | 2420-8124 | |
dc.identifier.doi | 10.52965/001c.39576 | |
dc.identifier.uri | http://hdl.handle.net/10150/667894 | |
dc.description.abstract | Monoamine oxidase inhibitors (MAOI) are a class of drugs that were originally developed for the treatment of depression but have since been expanded to be used in management of affective and neurological disorders, as well as stroke and aging-related neurocognitive changes. Ranging from irreversible to reversible and selective to non-selective, these drugs target the monoamine oxidase (MAO) enzyme and prevent the oxidative deamination of various monoamines and catecholamines such as serotonin and dopamine, respectively. Tyramine is a potent releaser of norepinephrine (NE) and is found in high concentrations in foods such as aged cheeses and meats. Under normal conditions, NE is unable to accumulate to toxic levels due to the presence of MAO-A, an enzyme that degrades neurotransmitters, including NE. When MAO-A is inhibited, the capacity to handle tyramine intake from the diet is significantly reduced causing the brain to be vulnerable to overstimulation of postsynaptic adrenergic receptors with as little as 8-10 mg of tyramine ingested and can result in life-threatening blood pressure elevations. In addition to adverse reactions with certain foods, both older and newer MAOIs can negatively interact with both sympathomimetic and serotonergic drugs. In general, patients on a MAOI want to avoid two types of medications: those that can elevate blood pressure via sympathomimetic actions (e.g., phenylephrine and oxymetazoline) and those that can increase serotonin levels via 5-HT reuptake inhibition (e.g., dextromethorphan, chlorpheniramine, and brompheniramine). Illicit drugs that stimulate the central nervous system such as ecstasy (MDMA, 3,4-methylenedioxymethamphetamine) act as serotonin releasers. Patient involvement is also crucial to ensure any interaction within the healthcare setting includes making other providers aware of a MAOI prescription as well as avoiding certain OTC medications that can interact adversely with MAOIs. © 2022, Open Medical Publishing. All rights reserved. | |
dc.language.iso | en | |
dc.publisher | Open Medical Publishing | |
dc.rights | Copyright © 2022 The Author(s). Open Medical Publishing has chosen to apply the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published under its name. | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | |
dc.subject | bleeding | |
dc.subject | drug interactions | |
dc.subject | ecstasy | |
dc.subject | headache | |
dc.subject | hypertensive crisis | |
dc.subject | insomnia | |
dc.subject | Monoamine oxidase inhibitors | |
dc.subject | sexual dysfunction | |
dc.subject | weight gain | |
dc.title | Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors | |
dc.type | Article | |
dc.type | text | |
dc.contributor.department | College of Medicine-Tucson, University of Arizona | |
dc.identifier.journal | Health Psychology Research | |
dc.description.note | Open access journal | |
dc.description.collectioninformation | This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu. | |
dc.eprint.version | Final published version | |
dc.source.journaltitle | Health Psychology Research | |
refterms.dateFOA | 2023-01-31T18:18:51Z |